摘要
目的探讨经门静脉灌注华蟾素注射液联合经导管动脉内栓塞化疗(TACE)治疗肝癌合并门静脉癌栓患者的疗效及安全性。方法将确诊且不能经手术治疗的肝癌合并门静脉癌栓患者66例分组方法分为对照组(n=32)与观察组(n=34),对照组采用TACE治疗,观察组在对照组基础上采用华蟾素门静脉持续灌注治疗,随访2组的生存情况及预后。结果观察组的中位生存期为6.5个月,半年生存率为61.76%(21/34),1年生存率为34.38%(11/32);对照组中位生存期为4.5个月,半年生存率为11.76%(4/34),1年生存率为6.25%(2/32),2组差异有统计学意义(P<0.05)。多因素分析显示有无华蟾素门静脉灌注、癌栓分型及肿瘤大小是影响肝癌并门静脉癌栓患者生存期的独立危险因素。2组的不良反应发生率无显著差异(P>0.05)。结论华蟾素注射液门静脉灌注联合TACE治疗在不增加不良反应的基础上生存期更长。
Objective To explore the clinical efficacy and safety of portal perfusion of cinobufacini injection combined with transhepatic arterial chemoembolization（ TACE） in treatment of liver cancer patients complicated with portal vein tumor thrombus（ PVTT）. Methods A total of 66 patients diagnosed as liver cancer complicated with PVTT were randomly divided into control group（ n = 32） and observation group（ n = 34）. Control group was treated with TACE,on which basis observation group was added with persistent portal perfusion of cinobufacini injection. Survival conditions and prognosis were followed up in both groups. Results In observation group and control group,the median survival time were 6. 50 and 4. 50 months,the half-year survival rates were61. 76%（ 21 /34） and 11. 76%（ 4 /34）,and the 1-year survival rates were 34. 38%（ 11 /32） and6. 25%（ 2 /32）,and there were significant differences between two groups（ P〈0. 05）. Multivariate analysis showed that whether there was portal perfusion of cinobufacini injection,the types of tumorthrombus,and tumor size were the independent risk factors for the survival time of patients with liver cancer complicated with PVTT. There was no significant difference between two groups in adverse reactions（ P〉0. 05）. Conclusion Portal perfusion of cinobufacini injection combined with TACE can prolong the survival time of patients with liver cancer complicated with PVTT without increasing the adverse reactions.
出处
《实用临床医药杂志》
CAS
2016年第21期31-33,58,共4页
Journal of Clinical Medicine in Practice
基金
上海市卫生局青年科研项目(20124Y030)
上海市中医药事业发展三年行动计划(重大研究)(ZYSNXD-CC-ZDYJ025)
